<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247077</url>
  </required_header>
  <id_info>
    <org_study_id>DLL-159361</org_study_id>
    <nct_id>NCT01247077</nct_id>
  </id_info>
  <brief_title>Neuropsychologic and Immunological Evaluation in Treatment of Thyroid Diseases. Is Selenium Efficient?</brief_title>
  <official_title>Neuropsychologic and Immunological Evaluation in Treatment of Thyroid Diseases. Is Selenium Efficient?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Graves thyrotoxicosis is a common autoimmune disease. Patients suffer at diagnosis from
      weight loss, increased heart rate and stress intolerance. Some patients have difficulties in
      regaining quality of life. Diagnosis is found through elevated thyroid hormones thyroxin,
      suppressed TSH (thyroid stimulating hormone) from the pituitary and elevated stimulatory
      antibodies, TRAb (thyrotropin receptor antibody) to the thyroid. Selenium is sparse in
      western Europe. This compound has important function in thyroid hormone metabolism and on the
      immune system. It is not known whether addition of selenium affects the well being of
      patients with Graves´thyrotoxicosis. The subject of this study is to investigate this
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the County of Södermanland we include 44 patients with Graves´thyrotoxicosis. They are
      treated with methimazole and thyroxin, and randomised to selenium or placebo.
      Neuropsychological investigation is performed, before medical treatment is commenced and
      repeated after 9 month. Serum concentration of thyroid hormon levels, autoantibodies and
      selenium are followed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on neuropsychological well-being</measure>
    <time_frame>Inclusion going on until the end of 2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Potential effect on autoantibodies</measure>
    <time_frame>Inclusion for the rest of 2011</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>QoL Before and After 9 Month of Medical Treatment of Graves´Thyrotoxicosis</condition>
  <condition>Potential Effect of Selenium</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo and thyroxin + methimazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>selenium</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>selenium + methimazole + thyroxin</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>selenium</intervention_name>
    <description>200 ug selenium once daily</description>
    <arm_group_label>selenium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New diagnose of autoimmune thyrotoxicosis

          -  biochemically proven with increased thyroxin

          -  low TSH and elevated TRAb/or positive scintigraphy.

          -  Age 18 - 55. Willing to participate -

        Exclusion Criteria:

          -  No previous head trauma,

          -  No difficulties with swedish language,

          -  No medication which could affective neuropsychological testing,

          -  No planned or ongoing pregnancies.

          -  Normal intellectual capacity.

          -  No severe ophthalmopathy, or other severe disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Calissendorff, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jan Calissendorff, Medical clinic, Eskilstuna, Sweden</name>
      <address>
        <city>Eskilstuna</city>
        <state>Södermanland</state>
        <zip>63188</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emil Mikulski</name>
      <address>
        <city>Eskilstuna</city>
        <zip>63188</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Jan Calissendorff, MD</investigator_full_name>
    <investigator_title>Senior consultant</investigator_title>
  </responsible_party>
  <keyword>selenium</keyword>
  <keyword>neuropsychological testing</keyword>
  <keyword>autoantibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

